[go: up one dir, main page]

AU2001245741A1 - Antisense inhibition of adam10 expression - Google Patents

Antisense inhibition of adam10 expression

Info

Publication number
AU2001245741A1
AU2001245741A1 AU2001245741A AU4574101A AU2001245741A1 AU 2001245741 A1 AU2001245741 A1 AU 2001245741A1 AU 2001245741 A AU2001245741 A AU 2001245741A AU 4574101 A AU4574101 A AU 4574101A AU 2001245741 A1 AU2001245741 A1 AU 2001245741A1
Authority
AU
Australia
Prior art keywords
antisense inhibition
adam10 expression
adam10
expression
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245741A
Inventor
Thomas P. Condon
Shin Cheng Flournoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2001245741A1 publication Critical patent/AU2001245741A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001245741A 2000-03-17 2001-03-15 Antisense inhibition of adam10 expression Abandoned AU2001245741A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/527,154 US6228648B1 (en) 2000-03-17 2000-03-17 Antisense modulation of ADAM10 expression
US09527154 2000-03-17
PCT/US2001/008259 WO2001071008A1 (en) 2000-03-17 2001-03-15 Antisense inhibition of adam10 expression

Publications (1)

Publication Number Publication Date
AU2001245741A1 true AU2001245741A1 (en) 2001-10-03

Family

ID=24100317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245741A Abandoned AU2001245741A1 (en) 2000-03-17 2001-03-15 Antisense inhibition of adam10 expression

Country Status (3)

Country Link
US (2) US6228648B1 (en)
AU (1) AU2001245741A1 (en)
WO (1) WO2001071008A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
US20080139512A1 (en) * 2002-09-25 2008-06-12 Quick-Med Technologies, Inc. Method for minimizing or avoiding adverse effects of vesicants
EP1623995A1 (en) * 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
US8210051B2 (en) * 2004-12-03 2012-07-03 General Electric Company System and method for cyclic testing
US7353715B2 (en) * 2004-12-03 2008-04-08 General Electric Company System, apparatus and method for testing under applied and reduced loads
US8210050B2 (en) * 2004-12-03 2012-07-03 General Electric Company Apparatus and system for cyclic testing
EP1984500A2 (en) * 2006-01-13 2008-10-29 Vanderbilt University Adam10 and its uses related to infection
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
AU2009253780B2 (en) 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CN113876945A (en) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 Liposome composition comprising adjuvant for activating or increasing TLR2 activity and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5922546A (en) * 1997-08-25 1999-07-13 Smithkline Beecham Corporation Human disintegrin metalloprotease KUZ gene

Also Published As

Publication number Publication date
US6228648B1 (en) 2001-05-08
US20030211610A1 (en) 2003-11-13
WO2001071008A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
AU2001229493A1 (en) Antisense modulation of mekk2 expression
AU2002213002A1 (en) Antisense inhibition of caspase 6 expression
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2002227435A1 (en) Antisense modulation of calreticulin expression
AU2002253836A1 (en) Aptamer-mediated regulation of gene expression
AU6111000A (en) Inhibitors of viral helcase
AU2001277003A1 (en) Antisense inhibition of her-3 expression
AU1488501A (en) Methods of inhibiting metastasis
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU2001245741A1 (en) Antisense inhibition of adam10 expression
AU2001283443A1 (en) Antisense modulation of hpk/gck-like kinase expression
AU2001257220A1 (en) Antisense modulation of inhibitor of dna binding-1 expression
AU4369000A (en) Inhibition of complement action
AU2001288968A1 (en) Antisense modulation of btak expression
AU2002226064A1 (en) Antisense modulation of talin expression
AUPQ629000A0 (en) Inhibition of fungi
AU2001252884A1 (en) Method of dopamine inhibition using l-threo-methylphenidate
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2001234462A1 (en) Antisense modulation of cot oncogene expression
AU2001287136A1 (en) Antisense modulation of glioma-associated oncogene-1 expression
AU2003239864A1 (en) Antisense moodulation of kinesin-like 1 expression
AU2001292947A1 (en) Methods for inhibition of viral infection
AU2001234461A1 (en) Antisense modulation of daxx expression
AU2001288908A1 (en) Antisense modulation of mekk3 expression
AU2001288907A1 (en) Antisense modulation of a20 expression